Latest / Community Health Media
Dr. Erica Mayer & Dr. Seth Wander - Biomarker Testing & Precision Targeting in the PI3K Pathway
How is molecular profiling reshaping HR+ metastatic breast cancer treatment?
In this episode of CHM Conversations, Dr. Erica Mayer and Dr. Seth Wander navigate the evolving landscape of endocrine resistance and the PI3K/AKT pathway. They discuss the shifting roles of ESR1 and PIK3CA mutations, the rise of ctDNA in clinical sequencing, and the practicalities of integrating newer therapies like capivasertib.
From proactive toxicity monitoring to the future of combination care, this discussion explores the next era of precision medicine in HR+ breast cancer.
An essential resource for clinicians…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.